Medtronic PLC $MDT Shares Acquired by Souders Financial Advisors

Souders Financial Advisors lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 58.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,017 shares of the medical technology company’s stock after purchasing an additional 1,476 shares during the quarter. Souders Financial Advisors’ holdings in Medtronic were worth $350,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of MDT. Achmea Investment Management B.V. increased its holdings in shares of Medtronic by 6.4% in the second quarter. Achmea Investment Management B.V. now owns 356,220 shares of the medical technology company’s stock valued at $31,052,000 after buying an additional 21,408 shares in the last quarter. SouthState Corp boosted its holdings in shares of Medtronic by 42.0% during the second quarter. SouthState Corp now owns 1,896 shares of the medical technology company’s stock worth $165,000 after purchasing an additional 561 shares during the period. Andra AP fonden grew its position in Medtronic by 94.3% during the second quarter. Andra AP fonden now owns 62,629 shares of the medical technology company’s stock valued at $5,459,000 after purchasing an additional 30,400 shares in the last quarter. Outfitter Financial LLC increased its stake in Medtronic by 2.6% in the 2nd quarter. Outfitter Financial LLC now owns 13,318 shares of the medical technology company’s stock valued at $1,161,000 after buying an additional 335 shares during the period. Finally, Resona Asset Management Co. Ltd. purchased a new stake in Medtronic in the 2nd quarter worth approximately $33,146,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. William Blair upgraded shares of Medtronic to a “hold” rating in a report on Friday, July 11th. The Goldman Sachs Group lowered their target price on Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research note on Wednesday, October 1st. BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, July 11th. Mizuho lifted their price target on Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $102.82.

Medtronic Stock Performance

Shares of NYSE MDT opened at $90.10 on Friday. The business’s 50-day simple moving average is $94.21 and its 200-day simple moving average is $89.88. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The firm has a market cap of $115.57 billion, a price-to-earnings ratio of 24.82, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter last year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.